A recent study demonstrated that temozolomide can induce two TP53 missense mutations (R110C/c.328 C>T and R175H/c.524 G>A) in glioma spheres derived from primary GBM, and that these mutations may facilitate epithelial‐to‐mesenchymal transition.40 Here, TP53 is linked to central nervous system cancer.